Anti-tumor Efficacy and Safety of the BAG3/HSP70 Inhibitor YM-1 ina Triple Negative Breast Cancer Model
DOI:
https://doi.org/10.61173/qk908679Keywords:
BAG3 inhibition, BAG3, YM-1, TNBC, doxorubicin, HSP:70Abstract
Patients who treat with TNBC are usually with intense chemotherapy. Recently, BAG3 has been suggested as a
potential therapeutic target for cancer. However, inhibiting BAG3 for therapy may result in unintended damage to
cardiomyocytes. Thus, this research proposal will test whether or not the inhibition of BAG3 will significantly affect
the heart while still having potent anti-tumor efficacy. Human TNBC cell line BT-549 cells will be inoculated into CB17/SCID mice. When the tumor grows to 100 mm3, mice will be intraperitoneally injected with different doses of YM1, an inhibitor of BAG3/HSP70. The clinically used TNBC chemotherapy drug doxorubicin will be used as the positive
control. The tumor growth, expressed as the change in tumor volume and tumor growth inhibition percentage (TGI),
will be measured. Troponin I level in the serum, ECG measurement, and Hematoxylin and Eosin staining will be used to
assess heart damage. The results of our study will indicate whether the animals will tolerate the BAG3 inhibitor, YM-1,
at its effective doses and whether inhibition of BAG3 may be a better option, particularly regarding unwanted effects on
cardiomyopathy, compared to standard of care in TNBC. Future investigations are warranted.
References
[1] “Treatment of Triple-Negative Breast Cancer: Treatment of TNBC.” American Cancer Society, American Cancer Society, 12 Apr. 2022, https://www.cancer.org/cancer/breast-cancer/ treatment/treatment-of-triple-negative.html.
[2] Isakoff, Steven J. “Triple-negative breast cancer: role of specific chemotherapy agents.” Cancer journal (Sudbury, Mass.) vol. 16,1 (2010): 53-61. doi:10.1097/PPO.0b013e3181d24ff7
[3] Shields et al. BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. Oncotarget. 2018;9(21):15673-15690
[4] Myers, Valerie D et al. “The Multifunctional Protein BAG3: A Novel Therapeutic Target in Cardiovascular Disease.” JACC. Basic to translational science vol. 3,1 (2018): 122-131. doi:10.1016/j.jacbts.2017.09.009
[5] Kirk, Jonathan A., et al. “Therapeutic Targeting of BAG3: Considering Its Complexity in Cancer and Heart Disease.” Journal of Clinical Investigation, vol. 131, no. 16, 16 Aug. 2021, https://doi.org/10.1172/jci149415. Accessed 1 July 2022.
[6] Meriin, Anatoli B et al. “Hsp70-Bag3 complex is a hub for proteotoxicity-induced signaling that controls protein aggregation.” Proceedings of the National Academy of Sciences of the United States of America vol. 115,30 (2018): E7043-E7052. doi:10.1073/pnas.1803130115
[7] De Marco, Margot et al. “Role of BAG3 in cancer progression: A therapeutic opportunity.” Seminars in cell & developmental biology vol. 78 (2018): 85-92. doi:10.1016/ j.semcdb.2017.08.049
[8] Denard, Bray et al. “CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.” BMC cancer vol. 18,1 813. 13 Aug. 2018, doi:10.1186/s12885-018-4724-8
[9] Chatterjee, Kanu et al. “Doxorubicin cardiomyopathy.” Cardiology vol. 115,2 (2010): 155-62. doi:10.1159/000265166
[10] Volkova, Maria, and Raymond Russell 3rd. “Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.” Current cardiology reviews vol. 7,4 (2011): 214-20. doi:10.2174/157340311799960645
[11] Mitry, Maria A, and John G Edwards. “Doxorubicin induced heart failure: Phenotype and molecular mechanisms.” International journal of cardiology. Heart & vasculature vol. 10 (2016): 17-24. doi:10.1016/j.ijcha.2015.11.004 Dean&Francis
[12] Sherman, Michael Y, and Vladimir Gabai. “The role of Bag3 in cell signaling.” Journal of cellular biochemistry vol. 123,1 (2022): 43-53. doi:10.1002/jcb.30111
[13] Li, Xiaokai et al. “Validation of the Hsp70-Bag3 proteinprotein interaction as a potential therapeutic target in cancer.” Molecular cancer therapeutics vol. 14,3 (2015): 642-8. doi:10.1158/1535-7163.MCT-14-0650
[14] Chu, Victor, et al. “Method for Non-Invasively Recording Electrocardiograms in Conscious Mice.” BMC Physiology, vol. 1, no. 1, 25 June 2001, pp. 1–6., https://doi.org/10.1186/1472- 6793-1-6. Accessed 2 July 2022.
[15] Colvin, Teresa A et al. “Hsp70-Bag3 interactions regulate cancer-related signaling networks.” Cancer research vol. 74,17 (2014): 4731-40. doi:10.1158/0008-5472.CAN-14-0747
[16] Zhu, Wuqiang et al. “A mice model for juvenile doxorubicin-induced cardiac dysfunction.” Pediatric research vol. 64,5 (2008): 488-94. doi:10.1203/PDR.0b013e318184d732
[17] Tan, Swee Yaw, et al. “A Simplified Clinical Electrocardiogram Score for the Prediction of Cardiovascular Mortality.” Clinical Cardiology, vol. 32, no. 2, 12 Feb. 2009, pp. 82–86., https://doi.org/10.1002/clc.20288. Accessed 4 July 2022.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
